Navigation Links
New Review of Novel Intranasal Delivery of Sumatriptan as a Route to Rapid and Sustained Relief in the Acute Treatment of Migraine
Date:11/17/2016

LONDON, November 17, 2016 /PRNewswire/ --

Deborah I Friedman, US Neurology , 2016;12(2):84-9: https://doi.org/10.17925/USN.2016.12.02.84

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)
Published recently in US Neurology, the peer-reviewed journal from touchNEUROLOGY, Deborah I Friedman discusses a new treatment in migraine. This condition remains a common debilitating condition that exerts a high social and economic burden worldwide. Despite the widespread availability of various medications for migraine, many patients are dissatisfied with their treatment. Rapid and effective treatment at an early stage in an attack is vital in migraine to prevent central sensitization leading to attacks that are difficult to treat. Most migraineurs prefer oral medications but this is not always the most rapid or efficient route into the bloodstream. Intranasal administration of migraine treatment provides a rapid, convenient and reliable alternative to oral and other routes. AVP-825 is an intranasal medication delivery system approved by the US Food and Drug Administration in January 2016 as ONZETRA™ Xsail™ (sumatriptan nasal powder [Avanir Pharmaceuticals, Aliso Viejo, CA]) for the acute treatment of migraine with or without aura in adults. AVP-825 contains low dose sumatriptan powder and takes advantage of some unique aspects of the nasal anatomy to confer rapid pain relief in the acute treatment of migraine. In two Phase III trials, AVP-825 was well tolerated and showed significantly faster migraine pain relief and relief from other symptoms including photophobia, phonophobia, and nausea than placebo or oral sumatriptan. This benefit was achieved with substantially lower drug exposure than oral sumatriptan. Additional analyses of data from the Phase III trials show that significantly more patients with migraine receiving AVP-825 reported clinically meaningful relief, sustained relief, pain freedom, lower migraine-related disability and more consistent relief across multiple attacks than those receiving oral sumatriptan. The rapid and sustained action of AVP-825 and its convenience creates the potential for this unique treatment to reduce the burden of migraine in many patients.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/USN.2016.12.02.84

Disclosure: Deborah I Friedman is a consultant for Allergan, Avanir, Supernus, Teva Pharmaceuticals, Eli Lilly, Zosano, and Alder Biopharmaceuticals. She is a speaker for Avanir, Supernus, Teva Pharmaceuticals and has received research support from Merck, Autonomic Technologies, Inc., and Eli Lilly.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals


'/>"/>
SOURCE touchNEUROLOGY.com
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Insomnia Pipeline Landscape and Therapeutics Development Market Review H2 2016
2. Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
3. Degenerative Scoliosis Global Clinical Trials Review, H2, 2016
4. Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
5. World Heart Federation Previews Global Roadmap to Tackle Cholesterol
6. Novel Intraocular Pressure-Lowering Agent, Latanoprostene Bunod, Under Review
7. Emmaus New Drug Application for Sickle Cell Disease Accepted for Review by FDA
8. Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
9. Market of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles
10. A New Review Defines Essential Components of Comprehensive Care of Patients With Spastic Paresis and the Need for a Long-Term Commitment
11. New Expert Review of Adaptive Servo-Ventilation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... ... August 02, 2018 , ... What: The Wharton School is pleased ... which will allow up to five business reporters who cover aspects of public policy ... this year. Each funding opportunity covers the cost of tuition, course materials, most ...
(Date:8/2/2018)... ... August 02, 2018 , ... Clay and Associates DDS, PLC is excited to ... will join Dr. John Clay and Dr. Shaun O’Neill as an associate dentist to ... all of their patients' dental hygiene, encapsulates the core values of the professional dental ...
(Date:8/2/2018)... ... 02, 2018 , ... Shady Grove Fertility (SGF), ... expanding into Florida with the opening of a location in Tampa ... women’s health care throughout Central Florida. This is SGF’s first location in the ...
Breaking Medicine Technology:
(Date:8/11/2018)... ST. PETERSBURG, Fla. (PRWEB) , ... August 10, 2018 , ... ... health and wellness of children in the region by utilizing a population health perspective ... of a population by ensuring families are being treated at the right facility or ...
(Date:8/9/2018)... ... August 09, 2018 , ... Lyme disease is one ... year skyrocketing to an estimated 329,000 – a 25-fold increase since surveillance began in ... disease can be found all 50 states and the District of Columbia. Yet, Lyme ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the generosity of ... distributors, customers, and employees, the newly established Isagenix Legacy Foundation raised ... goal. 100 percent of the donations will fund grants to nonprofit organizations that ...
(Date:8/7/2018)... , ... August 07, 2018 , ... ... 30 talented nursing students selected to receive the 2018 Board of Directors ... experience the rewarding field of psychiatric-mental health nursing and develop the next generation ...
(Date:8/3/2018)... ... August 03, 2018 , ... Lucyd Pte ... to announce the launch of its online store. The Lucyd eShop will feature ... other innovations in spectacles. , The eShop will have a number of ...
Breaking Medicine News(10 mins):